Basal forebrain volume and concurrent hallucinations and mild cognitive impairment in Parkinson's disease

Sabrina M. Adamo[1,2], Vaishali Mutreja[1], Marta Statucka[1], Batu Kaya[1], Taylor W. Schmitz[3], Anthony C. Ruocco[2], Melanie Cohn[1,2]

[1]Krembil Brain Institute, Toronto Western Hospital UHN, Toronto, Ontario, Canada; [2]Graduate Department of Psychological Clinical Science, University of Toronto, Ontario, Canada; [3]Department of Physiology and Pharmacology, University of Western Ontario, London, Ontario, Canada

ORCiDs: Adamo, S: https://orcid.org/0000-0002-6105-9984; Mutreja, V: https://orcid.org/0000-0001-6909-2028; Statucka, M: https://orcid.org/0000-0003-0241-2992; Kaya, B: https://orcid.org/0000-0003-0484-1467; Schmitz, TW: https://orcid.org/0000-0003-0585-7524; Ruocco, A: https://orcid.org/0000-0002-1942-7181; Cohn, M: https://orcid.org/0000-0003-2921-7505

Corresponding author: Dr. Melanie Cohn, melanie.cohn@uhn.ca

Address: Neuropsychology Clinic 4F-409, Toronto Western Hospital UHN, 399 Bathurst Street, Toronto, Ontario, Canada, M5T 2S8

Word count: 3478

Abstract: 249 words

References: 41

Financial Disclosure/Conflict of Interest: none

Funding Sources for study: Canadian Institutes of Health Research (CIHR) and UHN Collaborative Academic Practice.

ABSTRACT

Background

Visual hallucinations (VH) and mild cognitive impairment (MCI) often co-occur in Parkinson's Disease (PD). Each symptom in isolation is associated with cholinergic basal forebrain (BF) atrophy. However, it is unclear whether BF integrity relates to one symptom preferentially or to their co-occurrence, and whether this relationship is specific to the nucleus basalis of Meynert (Ch4 & Ch4p) or extends to other BF nuclei (Ch1-2 & Ch3).

Objectives

To bridge the literature on MCI, VH, and the BF by examining associations between total and subregional BF volumes with VH, MCI, and concurrent symptomology.

Methods

We used clinical and structural MRI data in PD patients (n=296) with or without VH (n=75; n=221), and with intact cognition or MCI (n=115; n=181), evaluated prior to deep brain stimulation. One-way ANCOVAs were run for each region (total BF, Ch1-2, Ch3, Ch4, and Ch4p). The independent variable was either cognitive status, VH status, or a combined factor with three levels (Intact Cognition-noVH, MCI-noVH, and MCI-VH), and covariates included intracranial volume, age, levodopa-equivalent dose, and dopamine agonist therapy (yes/no).

Results

We demonstrate main effects of MCI on BF (ω_p^2=.02), Ch4 (ω_p^2 = .02), and Ch1-2 (ω_p^2=.02) volumes, but not of VH. Subgroup analyses show reduced BF and Ch4 volumes in patients with both symptoms (d =0.44) relative to patients with neither.

Conclusions

We show dissociations within the cholinergic system in PD, where reduced volume of different BF nuclei relates to MCI only versus the combination of symptoms. We provide support for the "cholinergic phenotype".

Keywords: psychosis, cholinergic nuclei, cognitive decline, structural MRI, non-motor symptoms, voxel-based morphometry

INTRODUCTION

Non-motor symptoms such as visual hallucinations (VH) and mild cognitive impairment (MCI) are common in Parkinson's disease (PD) [1,2]. Each symptom is a risk factor for the other and for the development of dementia, and their combination may reflect a "malignant phenotype" associated with a rapid course towards dementia [3]. While the relationship between VH and MCI is not yet fully understood, cholinergic depletion stemming from basal forebrain (BF) degeneration may be a key contributor to each symptom. Pasquini et al. [4] proposed a "cholinergic phenotype" comprising the presence of MCI, VH, as well as other symptoms (e.g., gait problems, sleep disturbances, and olfactory impairment). Importantly, this proposal is based on a recent review of neuroimaging and post-mortem pathology studies showing BF alterations in PD-VH and PD-MCI in isolation, rather than in patients with concomitant symptomatology, as studies rarely report the co-occurrence of these symptoms.

The BF, which is the main sources of acetylcholine to the brain, is comprised of four cholinergic nuclei (Ch1 to Ch4). Ch1-2 project mainly to the hippocampi, Ch3 projects to the olfactory bulb and entorhinal cortex, and Ch4 [also referred to as the nucleus basalis of Meynert (NBM) and can be segmented into Ch4 and Ch4 posterior (Ch4p)] projects to the neocortex and basolateral amygdala [5,6]. Ch4 alterations are associated with VH [7] and with cognitive decline [8,9] in PD. In addition, reduced white matter tract integrity of BF projections has been shown in PD-VH compared with PD-noVH and controls groups [10], and in the Ch4 nuclei of PD-MCI patients compared with PD patients with intact cognition [8]. Lastly, post-mortem pathology studies showed a buildup of Lewy bodies in Ch4 of PD patients with well-formed VH as well as with PD dementia [11]. To date, there is limited research on the other anterior BF nuclei (Ch123), and of those limited studies, the reported results either pertain to Ch12 alone or

in combination with Ch3, while Ch3 has not been assessed on its own [6]. Specifically, only three studies examine these anterior BF nuclei in PD [7,9,12], none of which report volumetric loss in PD-MCI or PD-VH versus their cognitively intact or non-hallucinator counterparts [7,9] and only one study found differences in Ch123 as well as Ch4 between PD patients and healthy controls [12], but with no report of whether patients presented with VH or MCI.

Importantly, no imaging studies have investigated BF structural integrity in patients with concomitant presentation of PD-MCI and VH, and research on individual symptom type focuses primarily on the Ch4 within a single early PD dataset [i.e., Parkinson's Progression Markers Initiative (PPMI); [7–9], but see [12,13] for other cohorts]. This literature is further muddied by the confounding effects of dopaminergic medications [levodopa and dopamine agonists (DA)] which may also promote or exacerbate both MCI and VH symptoms [14].

The aim of this study is to bridge the two bodies of literature on VH, MCI, and the BF, and specifically the NBM (Ch4 and Ch4p), as the common neural substrate of PD-VH and PD-MCI while accounting for the confounding effects of dopaminergic pharmacotherapy. To achieve this, we performed a retrospective clinical chart review consisting of data from a multidisciplinary assessment (neuropsychology, neurology) and structural MRI completed prior to Deep Brain Stimulation (DBS). First, we hypothesize that VH and MCI are each associated with reduced total BF volume, and specifically the NBM, while taking into account levodopa/DA pharmacotherapy, as suggested by the literature on each symptom type. Second, we hypothesize that VH and MCI will have a compounding effect with smaller total BF and NBM volumes relative to the other groups presenting with one symptom or neither. As the other BF nuclei (Ch1-2, Ch3) have seldom been investigated [6], we also explore whether similar patterns are found in these regions of interest (ROIs).

METHODS

Participants

We conducted a chart review of PD patients who underwent multidisciplinary assessments and 3T MRI prior to DBS at the Toronto Western Hospital between January 2007 and August 2021. Exclusion criteria were: poor imaging quality, > six-month gap between the neuropsychological assessment and MRI, age < 40, neurological disorders other than PD (e.g. stroke, epilepsy, moderate to severe traumatic brain injury), severe mental illness (schizophrenia, personality disorders), severe scores on depression scales [Beck Depression Inventory-II (BDI-II) > 28, or Geriatric Depression Scale (GDS) > 19)]; [15,16], dementia (including PD dementia and dementia with Lewy bodies), limited English fluency, level I neuropsychological assessment [17], and missing VH data. A total of 296 people met inclusion criteria.

Sample characteristics

Demographic variables included age, sex, and years of education. Clinical variables included disease duration, levodopa equivalent daily dose (LEDD) [18], whether patients took DA (yes/no), motor symptom severity ON and OFF [Movement Disorders Society-Unified Parkinson's Disease Rating Scale part III (MDS-UPDRS-III)] [19], and percent levodopa response [(OFF–ON)/OFF*100%]. UPDRS-III [20] scores were converted to MDS-UPDRS-III scores for 218 patients using a validated transformation method [21].

Visual Hallucination Status

The presence and severity of current VH were coded on the MDS-UPDRS [19] item 1.2, based on written descriptions from neuropsychology reports, which summarize information collected during clinical interviews with patients alone (14%) or with patients and their care-

partners (86%), as well as information from their medical charts. This item ranges from 0-4 where 0=absence of hallucinations, 1=minor hallucinations, 2=well-formed hallucinations with preserved insight, 3=well-formed hallucinations with loss of insight, and 4=delusions. Scores were then binarized (yes/no), and patients with a score > 0 were included in the VH group. More fine-grained severity ratings are reported in **Supplementary Table S1**, but were not used in analyses due to their restricted range. Coding was completed by two independent raters with high interrater reliability (Cohen's Kappa>0.8), and discrepancies were resolved by consensus.

PD-MCI status

Cognitive diagnoses (PD-MCI versus intact cognition) were based on a level II neuropsychological assessment [17] and reached via consensus by licenced neuropsychologists (M.S. and M.C.) based on the presence of subjective cognitive decline, preserved independence with instrumental activities of daily living, and performance falling 1.5 SD below normative data on at least two independent neuropsychological tests. Visuoperceptual and spatial measures included the Benton Judgement of Line Orientation [22], Object Decision and Silhouette subtests from the Visual Object and Space Perception battery [23], and the Rey-Osterrieth (Rey-O) Figure Copy test [24]. Language tests comprised of the Boston Naming Test [25], Vocabulary subtest from the Wechsler Abbreviated Scale of Intelligence (WASI or WASI-II) [26,27], and the Category Verbal Fluency subtest from the Delis-Kaplan Executive Function System (D-KEFS) [28]. Memory tests included the California Verbal Learning Test-II [29], Logical Memory I and II subtests from the Wechsler Memory Scale-III (WMS-III) [30], and the Rey-O recall and recognition tests [24]. Attention and processing speed were assessed using the Trail Making Test-A (TMT-A) [31], D-KEFS Stroop colour and reading speed [28], and the Digit Span subtest from the WMS-III [30]. Lastly, executive functioning was assessed using the D-

KEFS Letter and Switching Verbal Fluency, D-KEFS Stroop interference and switching [28], TMT-B [31], Wisconsin Card Sorting Test [32], Matrix Reasoning subtest from the WASI or WASI-II [26,27], and the Conditional Associative Learning Test [33]. The BDI-II [15] or GDS [16] questionnaires were also collected and used for the exclusion criteria.

MRI acquisition and preprocessing

T1-weighted spoiled gradient recalled echo (SPGR) structural MRI scans were acquired on a 3T Signa MR system (GE Medical Systems, Milwaukee, WI). Images were resliced to 1x1x1mm voxel dimensions due to some variability in acquisition parameters (voxels acquired at <1mm^3, see **Supplementary Table S2**). MRIQC [34] was used for visual inspection. A voxel-based morphometry pipeline previously used in Alzheimer's disease [35,36] was implemented in SPM12 (http://www.fil.ion.ucl.ac.uk/spm) and MATLAB 2018a. First, images were bias-corrected to adjust for inhomogeneity and aligned into anterior/posterior commissure space before being affine co-registered to the Montreal Neurological Institute (MNI) template space. Grey matter (GM), white matter, cerebrospinal fluid, and total intracranial volume (TIV) segmentations were then generated on the T1 images and moved to a study-specific template using DARTEL. A study-specific template was used to minimize the geodesic distance from each subject to the population mean [37]. Non-linear modulation of GM images was done using the CAT12 toolbox, resulting in voxel-based indices of GM volume. There was no spatial smoothing applied to the volumes. Scans with poor imaging quality based on visual inspection or ones that failed CAT12 quality pipeline (e.g., homogeneity outliers) were excluded (n=4). Four bilateral BF ROIs (Ch1-2, Ch3, Ch4, Ch4p) derived from histological post-mortem studies [38] were segmented using a threshold of 50% (which is optimal for BF volume extraction [39]). As these ROIs are in MNI space, they were warped to the DARTEL study-specific template. The

four ROIs were combined into a single volumetric mask to generate a fifth ROI representing total BF volume. These five ROIs were used to extract GM volumetric data consisting of the sum of the total intensity of voxels within each ROI adjusted for the number of voxels.

Statistical analyses

Demographic and clinical characteristics were compared between cognitive status and VH status groups separately, using t-tests, Mann-Whitney U, and Chi-square tests. Cohen's *d* were reported as effect sizes. Although our preregistered statistical plan involved two-way ANCOVAs (MCI vs VH status) for each ROI to test for main effects of each symptom and their interaction, changes were warranted given the unbalanced case distributions and the infrequent occurrence of intact cognition with VH (n=14), which reduced statistical power (see **Supplementary Materials** for an explanation of protocol deviations). Therefore, the relationships between VH, MCI, and total BF volume were examined using three separate one-way analyses of covariance (ANCOVAs), where the independent variable was (1) cognitive status (MCI/intact Cognition), (2) VH status (yes/no), or (3) a combined "Diagnosis-VHstatus" (Dx-VHstat) factor to test the interaction. The Dx-VHstat factor excluded the rare Intact Cognition-VH group and had three levels: Intact Cognition-noVH, MCI-noVH, and MCI-VH. The dependent variable in each analysis was Total BF volume and covariates were TIV, age, LEDD, and DA (yes/no). Similar exploratory ANCOVAs were conducted separately for specific BF ROIs (Ch1-2, Ch3, Ch4 and Ch4p) to examine the potential preferential involvement of the NBM (Ch4 and Ch4p) in these symptoms. Statistical threshold was set at $p < .05$, and partial omega squared (ω_p^2) or Cohen's *d* were reported to convey effect sizes for ANCOVAs and post-hoc contrasts.

Data sharing

All data are part of the patients' clinical charts at Toronto Western Hospital, and patients have not provided consent to share their data publicly as this is a retrospective study.

RESULTS

Participant characteristics

Patient characteristics and related statistics are presented in **Tables 1** and **2** according to cognitive status and VH status, and in **Supplementary Table S1** for the combination of symptoms. Overall, 61% of patients presented with PD-MCI and 25% with VH, and these symptoms co-occur in 21% of the sample (subgroups: $n_{MCI\text{-}noVH} = 120$, $n_{MCI\text{-}VH} = 61$, $n_{Intact\ Cognition\text{-}noVH} = 101$, $n_{Intact\ Cognition\text{-}VH} = 14$). There were no differences between MCI or VH status groups for age, education, disease duration, LEDD, or MDS-UPDRS-III OFF scores. The MCI group had higher MDS-UPDRS-III ON scores and were less responsive to levodopa than the Intact Cognition group. The VH group had a higher proportion of people taking DA than the noVH group (84% vs 70%; *OR* = 2.28).

VH, MCI, and total basal forebrain volume

As shown in **Figure 1**, a one-way ANCOVA that included four covariates (TIV, age, LEDD, and DA), revealed a main effect of cognitive status where the MCI group had reduced total BF volume relative to the Intact Cognition group [$F(1, 290) = 6.92$, $p = .009$, $\omega_p^2 = .02$]. A second one-way ANCOVA revealed no main effect of VH [$F(1, 290) = 2.39$, $p = .12$, $\omega_p^2 = .00$; **Figure 2**]. A third one-way ANCOVA demonstrated a significant main effect of the Dx-VHstat grouping factor [$F(2, 275) = 3.51$, $p = .03$, $\omega_p^2 = .02$], which excludes the Intact Cognition-VH subgroup (**Figure 3**). Post-hoc contrasts revealed reduced BF volume in the MCI-VH relative to

the Intact Cognition-noVH group (d = 0.44), but not between Intact Cognition-noVH and MCI-noVH (d = 0.20) or MCI-noVH and MCI-VH (d = 0.22). These results suggest that smaller BF volume is associated with MCI, and more so in MCI-VH than Intact Cognition-noVH, while the VH factor alone failed to reach statistical significance.

VH, MCI, and regional basal forebrain nuclei

The same series of one-way ANCOVAs (cognitive status, VH status, Dx-VHstat) was run for the NBM ROIs (Ch4, Ch4p) separately. A main effect of cognitive status was found for Ch4 [$F(1, 290) = 5.80$, $p = .02$, $\omega_p^2 = .02$] but not Ch4p [$F(1, 290) = 0.55$, $p = .46$, $\omega_p^2 = .00$] (**Figure 1**). There was no main effect of VH status on Ch4 [$F(1, 290) = 3.04$, $p = .08$, $\omega_p^2 = .01$] nor on Ch4p [$F(1, 290) = 2.62$, $p = .11$, $\omega_p^2 = .01$] (**Figure 2**). A significant main effect of the Dx-VHstat factor was found for Ch4 [$F(2, 275) = 3.37$, $p = .03$, $\omega_p^2 = .02$] but not Ch4p [$F(2, 275) = 1.46$, $p = .23$, $\omega_p^2 = .00$] (**Figure 3**). Post-hoc contrasts for Ch4 showed that the MCI-VH group had smaller volumes than Intact Cognition-noVH (d = 0.44) but there were no significant differences between Intact Cognition-noVH and MCI-noVH (d = 0.20) or between MCI-noVH and MCI-VH (d = 0.20).

Next, the same three one-way ANCOVAs (cognitive status, VH status, and Dx-VHstat) were run on the anterior BF nuclei (Ch1-2 and Ch3). There was a main effect of cognitive status on the Ch1-2 volume [$F(1, 290) = 5.39$, $p = .02$, $\omega_p^2 = .02$] but not the Ch3 volume [$F(1, 290) = 2.37$, $p = .13$, $\omega_p^2 = .00$] (**Figure 1**). There were no main effects of VH status on Ch1-2 [$F(1, 290) = 0.08$, $p = .78$, $\omega_p^2 = .00$] or Ch3 [$F(1, 290) = 0.25$, $p = .62$, $\omega_p^2 = 0.00$] (**Figure 2**). Lastly, there were no significant main effects of the Dx-VHstat factor on Ch1-2 [$F(2, 275) = 1.56$, $p = .21$, ω_p^2

= .01] or Ch3 [$F(2, 275) = 1.02$, $p = .36$, $\omega_p^2 = .00$] (**Figure 3**). Together, these results suggest that reduced Ch1-2 volume relates to MCI regardless of the presence of VH, and reduced Ch4 volume relates to the co-occurrence of MCI and VH.

DISCUSSION

Our study is novel in that we examine the relationships between BF volumes, MCI and VH in a single cohort of individuals with long disease duration, and hence helps bridge the literature linking the BF to each type of symptom separately. Our data show that total BF volumes are smaller in PD patients with MCI than patients with intact cognition, but not in patients with VH versus noVH, when accounting for dopamine therapy. Regional analyses reveal that Ch4 and Ch1-2 are smaller in the PD-MCI group, but not Ch3 and Ch4p, and no differences are seen across BF nuclei between the VH and noVH groups. Secondly, patients with both MCI and VH have smaller total BF volumes than the Intact Cognition-noVH group, and at the specific nuclei level, a similar relationship is seen only with the Ch4 nucleus. These results suggest that while Ch1-2 is associated with MCI, the Ch4 nucleus is more closely linked with the concurrence of both MCI and VH supporting the malignant phenotype hypothesis.

Ch4 and Ch4p

Our study shows that Ch4 volume is most reduced in PD patients with concurrent MCI and VH (**Figure 3**). This is consistent with the few previous studies that demonstrated Ch4 volume loss as both a correlate and predictor of each symptom (in isolation) after five years [7–9], and related to visuospatial and attentional declines [12]. We did not find significant volumetric differences of the Ch4p nucleus between cognitive status or VH status. Only one

study [9], to our knowledge, reported on the Ch4p in PD, and found its volume was not predictive of developing PD-MCI within five years.

Ch1-2 and Ch3

A novel aspect of our study is that we examined the Ch1-2 and Ch3 nuclei separately and found that the volume of the Ch1-2 nuclei is smaller in PD-MCI compared to PD patients with intact cognition. The literature on the BF in PD rarely reports on findings in nuclei other than Ch4 [6]. Of those that did, some yielded null findings when comparing PD-MCI or PD-VH to their cognitively intact or non-hallucinator counterparts [7,9] or PD patients to controls [40]. In contrast, one study found Ch123 volumes were significantly smaller in *de novo* PD patients compared to controls, and were correlated with declines in visuospatial abilities and attention, but not memory [12]. The latter is surprising as the hippocampus is a major projection area of Ch1-2 and is critical to memory functioning. Another study showed no differences in Ch1-2 volumes between early-stage PD patients and controls, but demonstrated a significant relationship between Ch1-2 volume and visual memory in PD, which was mediated by hippocampal volumes [40]. Such relationships were not observed with measures of verbal memory nor between Ch4 volumes and verbal or visual memory.

The variability in findings between studies, including the present one, may be due to methodological differences in imaging analyses pipeline (e.g., using an ROI that combines Ch123 versus Ch1-2, normalization to the MNI template which is based on healthy young adult brains versus to a study-specific template). In addition, disease duration is likely an important contributor. Previous studies included PD patients at the early stage of the disease whereas we examined a PD cohort with longer disease duration. Notably, volume loss in BF nuclei could follow a similar posterior to anterior pattern of progression as that seen in the Alzheimer's

disease spectrum (from prodromal to dementia) [35], and thus Ch1-2 nuclei may be less affected at the early stages of PD.

Limitations

Our study has several limitations, which may be addressed in future research. First, PD patients in our sample were being considered for DBS due to dyskinesia and motor fluctuations. Therefore, our findings may not generalize to the entire PD population, including patients with late PD onset or those who would be ineligible for DBS due to older age, presence of dementia, or severe balance problems. However, the proportion of patients from our cohort presenting with concurrent VH and PD-MCI (21%) is similar to that reported in broader PD groups in a systematic review (28%) [1]. Furthermore, other studies investigating BF integrity in PD-MCI or as a predictor of future PD psychosis also leveraged data from a similar clinical group [10,12]. Second, while we focus on individual differences within PD, we cannot comment on the degree of atrophy or neurodegeneration given the absence of a healthy control group. We also do not have sufficient statistical power to examine sex differences which may be relevant across BF nuclei, but we provide data for males and females separately in **Supplementary Table S3** to inform future research. Third, the sample size differences across cells in our ANCOVAs reduced our statistical power and required adjustments in our pre-registered statistical plan. This was due to the rare occurrence of VH in the context of intact cognition (<5%). To address this, we opted to use one-way ANCOVAs to test for main effects of each cognitive and VH statuses, while using a combined variable excluding the rare diagnostic presentation of Intact Cognition-VH to test for the concurrence of both symptoms. Fourth, while we accounted for dopaminergic medications, we did not account for the degree of anticholinergic burden of patients' medication regimen, which may have a confounding relationship with cognition as shown in older adults

[41], as well as with VH. Lastly, while VBM imaging methodology can provide insights based on group data, it is not amenable for use at the individual level. To our knowledge, no in-vivo technique to date provides the necessary precision to measure BF integrity for clinical use.

CONCLUSIONS

Findings from the present study support the notion that PD is a heterogeneous disease with subtypes that reflect the involvement of not only dopaminergic dysfunction, but also cholinergic dysfunction. Furthermore, heterogeneity is present in the context of alterations within the cholinergic system, wherein reduced volume in different cholinergic BF nuclei is associated with different symptoms such as cognitive difficulties only (Ch1-2), and the co-occurrence of cognitive decline and VH (Ch4). Future work examining whether similar results are reflected distally in brain regions receiving cholinergic input from these BF nuclei would provide further support for this functional dissociation. Our study is also in line with the cholinergic phenotype proposed by Pasquini et al. [4] as we demonstrated that the co-occurrence of MCI and VH is associated with the BF volume loss. Future research is needed to examine the prevalence of the co-occurrence of other symptoms associated with this phenotype. This knowledge will contribute to the development of a unified method of assessing cholinergic compromise in PD, which would benefit the design of clinical trials targeting the cholinergic system and treatment planning in clinical care.

ACKNOWLEDGMENTS

The authors thank Bianca Iddiols and Megan Vaziri for their help with data extraction and coding.

AUTHORS' ROLES

Conceptualization: SA, MC. Design/methodology: SA, TS, AR, MC. Data curation: MS, MC (clinical data); SA, VM, BK, MC (MRI data); Neuroimaging analyses: SA, VM, BK, TS; Statistical analyses: SA, MC; Supervision: MC, AR, MS; Writing: SA, MC (original draft/review and editing), MS, BK, VM, AR, TS (review and editing). All authors reviewed and approved the final version of the manuscript. MC is the guarantor and accepts full responsibility for the finished work and/or the conduct of the study, had access to the data, and controlled the decision to publish.

COMPETING INTERESTS

None declared.

References

[1] Eversfield CL, Orton LD. Auditory and visual hallucination prevalence in Parkinson's disease and dementia with Lewy bodies: a systematic review and meta-analysis. Psychol Med 2019;49:2342–53. https://doi.org/10.1017/S0033291718003161.

[2] Hely MA, Reid WGJ, Adena MA, Halliday GM, Morris JGL. The Sydney Multicenter Study of Parkinson's disease: The inevitability of dementia at 20 years. Movement Disorders 2008;23:837–44. https://doi.org/10.1002/mds.21956.

[3] Goetz CG, Fan W, Leurgans S, Bernard B, Stebbins GT. The malignant course of "benign hallucinations" in Parkinson disease. Arch Neurol 2006;63:713–6. https://doi.org/10.1001/archneur.63.5.713.

[4] Pasquini J, Brooks DJ, Pavese N. The Cholinergic Brain in Parkinson's Disease. Mov Disord Clin Pract 2021;8:1012–26. https://doi.org/10.1002/mdc3.13319.

[5] Newman EL, Gupta K, Climer JR, Monaghan CK, Hasselmo ME. Cholinergic modulation of cognitive processing: Insights drawn from computational models. Front Behav Neurosci 2012;6:1–19. https://doi.org/10.3389/fnbeh.2012.00024.

[6] Slater NM, Melzer TR, Myall DJ, Anderson TJ, Dalrymple-Alford JC. Cholinergic Basal Forebrain Integrity and Cognition in Parkinson's Disease: A Reappraisal of Magnetic Resonance Imaging Evidence. Movement Disorders 2024. https://doi.org/10.1002/mds.30023.

[7] Barrett MJ, Blair JC, Sperling SA, Smolkin ME, Druzgal TJ. Baseline symptoms and basal forebrain volume predict future psychosis in early Parkinson disease. Neurology 2018;90:e1618–26. https://doi.org/10.1212/WNL.0000000000005421.

[8] Schulz J, Pagano G, Fernández Bonfante JA, Wilson H, Politis M. Nucleus basalis of Meynert degeneration precedes and predicts cognitive impairment in Parkinson's disease. Brain 2018;141:1501–16. https://doi.org/10.1093/brain/awy072.

[9] Ray NJ, Bradburn S, Murgatroyd C, Toseeb U, Mir P, Kountouriotis GK, et al. In vivo cholinergic basal forebrain atrophy predicts cognitive decline in de novo Parkinson's disease. Brain 2018;141:165–76. https://doi.org/10.1093/brain/awx310.

[10] Hepp DH, Foncke EMJ, Berendse HW, Wassenaar TM, Olde Dubbelink KTE, Groenewegen HJ, et al. Damaged fiber tracts of the nucleus basalis of Meynert in Parkinson's disease patients with visual hallucinations. Sci Rep 2017;7:1–10. https://doi.org/10.1038/s41598-017-10146-y.

[11] Kalaitzakis ME, Christian LM, Moran LB, Graeber MB, Pearce RKB, Gentleman SM. Dementia and visual hallucinations associated with limbic pathology in Parkinson's disease. Parkinsonism Relat Disord 2009;15:196–204. https://doi.org/10.1016/j.parkreldis.2008.05.007.

[12] Barrett MJ, Sperling SA, Blair JC, Freeman CS, Flanigan JL, Smolkin ME, et al. Lower volume, more impairment: reduced cholinergic basal forebrain grey matter density is associated with impaired cognition in Parkinson disease. J Neurol Neurosurg Psychiatry 2019;90:1251–6. https://doi.org/10.1136/jnnp-2019-320450.

[13] Pereira JB, Hall S, Jalakas M, Grothe MJ, Strandberg O, Stomrud E, et al. Longitudinal degeneration of the basal forebrain predicts subsequent dementia in Parkinson's disease. Neurobiol Dis 2020;139:104831. https://doi.org/10.1016/j.nbd.2020.104831.

[14] Dave S, Weintraub D, Aarsland D, Ffytche DH. Drug and Disease Effects in Parkinson's Psychosis: Revisiting the Role of Dopamine. Mov Disord Clin Pract 2020;7:32–6. https://doi.org/10.1002/mdc3.12851.

[15] Beck A, Steer R, Brown G. BDI-II: Beck Depression Inventory Manual. 2nd ed. San Antonio: Psychological Corporation; 1996.

[16] Yesavage JA, Brink TL, Rose TL, Lum O, Huang V, Adey M, et al. Development and validation of a geriatric depression screening scale: A preliminary report. J Psychiatr Res 1982;17:37–49. https://doi.org/10.1016/0022-3956(82)90033-4.

[17] Litvan I, Goldman JG, Tröster AI, Schmand BA, Weintraub D, Petersen RC, et al. Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. Movement Disorders 2012;27:349–56. https://doi.org/10.1002/mds.24893.

[18] Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE. Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Movement Disorders 2010;25:2649–53. https://doi.org/10.1002/mds.23429.

[19] Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Scale presentation and clinimetric testing results. Movement Disorders 2008;23:2129–70. https://doi.org/10.1002/mds.22340.

[20] Fahn S;, Elton RL, UPDRS Development Committee. Unified Parkinson's Disease Rating Scale. Recent Developments in Parkinson's Disease 1987;2:153–63.

[21] Hentz JG, Mehta SH, Shill HA, Driver-Dunckley E, Beach TG, Adler CH. Simplified conversion method for unified Parkinson's disease rating scale motor examinations. Movement Disorders 2015;30:1967–70. https://doi.org/10.1002/mds.26435.

[22] Calamia M, Markon K, Denburg NL, Tranel D. Developing a short form of Benton's Judgment of Line Orientation Test: an item response theory approach. Clin Neuropsychol 2011;25:670–84. https://doi.org/10.1080/13854046.2011.564209.

[23] Warrington EK, James M. The visual object and space perception battery. Bury St. Edmunds, England: Thames Valley Test Company; 1991.

[24] Meyers JE, Meyers KR. Rey Complex Figure Test and Recognition Trial. Odessa, FL: Psychological Assessment Records; 1991.

[25] Kaplan E, Goodglass H, Weintraub S. The Boston Naming Test-2nd edition. Philadelphia, PA: Lippincott Williams & Wilkins; 2001.

[26] Wechsler D. WASI: Wechsler Abbreviated Scale of Intelligence. San Antonio, TX: The Psychological Corporation; 1999.

[27] Wechsler D. WASI-II: Wechsler Abbreviated Scale of Intelligence - second edition. San Antonio, TX: The Psychological Corporation; 2011.

[28] Delis DC, Kaplan E, Kramer JH. Delis-Kaplan Executive Function System. San Antonio, TX: The Psychological Corporation; 2001.

[29] Delis DC, Kramer JH, Kaplan E, Ober B. California Verbal Learning Test - Second edition. San Antonio, TX: The Psychological Corporation; 2000.

[30] Wechsler D. Wechsler Memory Scale (WMS-III). San Antonio, TX: The Psychological Corporation; 1997.

[31] Heaton RK, Miller SW, Taylor MJ, Grant I. Revised comprehensive norms for an expanded Halstead-Reitan Battery: Demographically adjusted neuropsychological norms for African American and Caucasian adults, professional manual. Odessa, FL: Psychological Assessment Records; 2004.

[32] Heaton RK, Chelune G, Talley J, Kay GG, Curtiss G. Wisconsin Card Sorting Test. Odessa, FL: Psychological Assessment Records; 1993.

[33] Taylor AE, Saint-Cyr JA, Lang AE. Memory and learning in early Parkinson's disease: Evidence for a "frontal lobe syndrome." Brain Cogn 1990;13:211–32. https://doi.org/10.1016/0278-2626(90)90051-O.

[34] Esteban O, Birman D, Schaer M, Koyejo OO, Poldrack RA, Gorgolewski KJ. MRIQC: Advancing the automatic prediction of image quality in MRI from unseen sites. PLoS One 2017;12:e0184661. https://doi.org/10.1371/journal.pone.0184661.

[35] Schmitz TW, Spreng RN, Alzheimer's Disease Neuroimaging Initiative. Basal forebrain degeneration precedes and predicts the cortical spread of Alzheimer's pathology. Nat Commun 2016;7:13249. https://doi.org/10.1038/ncomms13249.

[36] Schmitz TW, Mur M, Aghourian M, Bedard MA, Spreng RN. Longitudinal Alzheimer's Degeneration Reflects the Spatial Topography of Cholinergic Basal Forebrain Projections. Cell Rep 2018;24:38–46. https://doi.org/10.1016/j.celrep.2018.06.001.

[37] Ashburner J. A fast diffeomorphic image registration algorithm. Neuroimage 2007;38:95–113. https://doi.org/10.1016/j.neuroimage.2007.07.007.

[38] Zaborszky L, Hoemke L, Mohlberg H, Schleicher A, Amunts K, Zilles K. Stereotaxic probabilistic maps of the magnocellular cell groups in human basal forebrain. Neuroimage 2008;42:1127–41. https://doi.org/10.1016/j.neuroimage.2008.05.055.

[39] Wang Y, Zhan M, Roebroeck A, De Weerd P, Kashyap S, Roberts MJ. Inconsistencies in atlas-based volumetric measures of the human nucleus basalis of Meynert: A need for high-resolution alternatives. Neuroimage 2022;259:119421. https://doi.org/10.1016/j.neuroimage.2022.119421.

[40] Berlot R, Pirtošek Z, Brezovar S, Koritnik B, Teipel SJ, Grothe MJ, et al. Cholinergic basal forebrain and hippocampal structure influence visuospatial memory in Parkinson's disease. Brain Imaging Behav 2022;16:118–29. https://doi.org/10.1007/s11682-021-00481-0.

[41] Richardson K, Fox C, Maidment I, Steel N, Loke YK, Arthur A, et al. Anticholinergic drugs and risk of dementia: case-control study. BMJ 2018;361:k1315. https://doi.org/10.1136/bmj.k1315.

Figure captions

Figure 1. Basal forebrain volumes between PD-Intact Cognition and PD-MCI.

Note. Standardized residuals after covarying total intracranial volume (TIV), age, total levodopa equivalent daily dose (LEDD), and dopamine agonist (yes/no).

Figure 2. Basal forebrain volumes between PD-noVH and PD-VH.

Note. Standardized residuals after covarying total intracranial volume (TIV), age, total levodopa equivalent daily dose (LEDD), and dopamine agonist (yes/no

Figure 3. Basal forebrain volumes between the Dx-VHstat factor: Intact Cognition-noVH, MCI-noVH, and MCI-VH.

Note. Standardized residuals after covarying total intracranial volume (TIV), age, total levodopa equivalent daily dose (LEDD), and dopamine agonist (yes/no). Individuals in the Intact-VH group were removed from the figure and respective analyses.

Table 1. Participant characteristics between PD-Intact Cognition and PD-MCI.

	Sample size Intact Cognition : MCI	Intact Cognition	MCI	Statistics
Characteristics				
% Female	115 : 181	30.4%	26.5%	$\chi^2 = 0.53$, $p = .47$, $d = 0.08$
Age	115 : 181	60.38 (7.77)	61.75 (7.41)	t = -1.51, $p = .13$, $d = -0.18$
Education	115 : 181	14.62 (3.19)	14.12 (3.04)	$U = 9338.5$, $p = .13$, $d = 0.17$
Disease Duration	115 : 181	9.24 (3.67)	10.18 (4.25)	$U = 9257.5$, $p = .11$, $d = 0.19$
MDS-UPDRS-III ON	115 : 181	14.54 (8.99)	17.83 (10.05)	$U = 8090$, $p < .001$*, $d = 0.38$
MDS-UPDRS-III OFF	111 : 178	37.45 (14.51)	40.00 (14.46)	$U = 8644.5$, $p = .07$, $d = 0.21$
% Levodopa response	111 : 178	62.40 (16.48)	56.64 (16.63)	$t = 2.87$, $p < .001$*, $d = 0.35$
Medications				
Total LEDD, mg	115 : 181	1345.75 (607.34)	1430.70 (633.67)	$t = -1.14$, $p = .25$, $d = -0.14$
DA (% yes)	115 : 181	73.9%	72.9%	$\chi^2 = 0.35$, $p = .85$, $d = 0.07$

Note. Data presented as mean (SD). MDS-UPDRS-III: Movement Disorders Society—Unified Parkinson's Disease Rating Scale part 3; LEDD: Levodopa Equivalent Daily Dose; DA: dopamine agonist. Levodopa response = ((OFF–ON)/OFF*100%)

Table 2. Participant characteristics between PD-noVH and PD-VH.

	Sample size No VH : VH	No VH	VH	Statistics
Characteristics				
% Female	221 : 75	30.8%	20.0%	$\chi^2 = 3.22$, $p = .07$, $d = 0.21$
Age	221 : 75	60.97 (7.68)	61.93 (7.24)	$t = -0.86$, $p = .39$, $d = -0.11$
Education	221 : 75	14.44 (3.15)	13.93 (2.95)	$U = 7654$ $p = .32$, $d = 0.12$
Disease Duration	221 : 75	9.56 (3.95)	10.57 (4.30)	$U = 7179$, $p = .08$, $d = 0.20$
MDS-UPDRS-III ON	221 : 75	16.58 (10.1)	16.47 (8.78)	$U = 8091.5$, $p = .76$, $d = 0.04$
MDS-UPDRS-III OFF	215 : 74	38.78 (15.01)	39.71 (13.01)	$U = 7410.5$, $p = .38$, $d = 0.03$
% Levodopa response	215 : 74	58.49 (17.69)	59.91 (13.86)	$t = -0.63$, $p = .53$, $d = -0.08$
Medications				
Total LEDD, mg	221 : 75	1365.67 (622.87)	1492.06 (621.54)	$t = -1.52$, $p = .13$, $d = -0.20$
DA (% yes)	221 : 75	69.7%	84.0%	$\chi^2 = 5.87$, $p = .02$*, $d = 0.28$

Note. Data presented as mean (SD). MDS-UPDRS-III: Movement Disorders Society—Unified Parkinson's Disease Rating Scale part 3; LEDD: Levodopa Equivalent Daily Dose; DA: dopamine agonist. Levodopa response = ((OFF–ON)/OFF*100%)


0.40
0.30
0.20
0.10
0.00
-0.10
-0.20
-0.30
-0.40
Standardized Residuals
Intact Cognition
MCI
*
*
*
BF total
Ch1-2
Ch3
Ch4
Ch4p


0.40
0.30
0.20
0.10
0.00
-0.10
-0.20
-0.30
-0.40
Standardized Residuals
NoVH
VH
BF total
Ch1-2
Ch3
Ch4
Ch4p


Intact-noVH
MCI-noVH
MCI-VH
Standardized Residuals
0.40
0.30
0.20
0.10
0.00
-0.10
-0.20
-0.30
-0.40
*
*
BF total
Ch1-2
Ch3
Ch4
Ch4p